Literature DB >> 12495475

Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.

Shigeki Koshida1, Tsutomu Narita, Hirofumi Kato, Shinobu Yoshida, Takashi Taga, Shigeru Ohta, Yoshihiro Takeuchi.   

Abstract

Recent studies have shown that the antiestrogen tamoxifen (TAM) can be used in the treatment of malignant neoplasms other than breast cancer. In the present study, we investigated the expression of estrogen receptor (ER) in six malignant rhabdoid tumor (MRT) cell lines. Alterations in MRT cell growth in response to estrogen or antiestrogens (4-hydroxytamoxifen (4-OHT), TAM, and ICI 182 780) were also investigated. RT-PCR and western blotting showed that ER-alpha was expressed in three of the six MRT cell lines. While 17-beta-estradiol (E2) did not significantly alter MRT cell line proliferation, the hydroxylated tamoxifen metabolite 4-OHT significantly inhibited the growth of all 6 MRT cell lines. However, the steroidal antiestrogen ICI 182 780 did not alter the proliferation of any of the MRT cell lines. 4-OHT induced apoptosis in both ER-alpha-negative and ER-alpha-positive MRT cell lines, as assessed by nuclear morphology and DNA fragmentation. Neither growth inhibition nor induction of apoptosis due to 4-OHT was blocked by the addition of excess E2. Our data suggested that 4-OHT induced cytotoxic effects against MRT cells, and that these effects were independent of ER expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495475      PMCID: PMC5926929          DOI: 10.1111/j.1349-7006.2002.tb01244.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  36 in total

Review 1.  Estrogen receptor beta--a new dimension in estrogen mechanism of action.

Authors:  J A Gustafsson
Journal:  J Endocrinol       Date:  1999-12       Impact factor: 4.286

2.  Gene expression of malignant rhabdoid tumor cell lines by reverse transcriptase-polymerase chain reaction.

Authors:  A Suzuki; S Ohta; M Shimada
Journal:  Diagn Mol Pathol       Date:  1997-12

3.  Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells.

Authors:  M Kandouz; M Siromachkova; D Jacob; B Chretien Marquet; A Therwath; A Gompel
Journal:  Int J Cancer       Date:  1996-09-27       Impact factor: 7.396

4.  Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children.

Authors:  J E Haas; N F Palmer; A G Weinberg; J B Beckwith
Journal:  Hum Pathol       Date:  1981-07       Impact factor: 3.466

Review 5.  Current status of tamoxifen use: An update for the surgical oncologist.

Authors:  A S Heerdt; P I Borgen
Journal:  J Surg Oncol       Date:  1999-09       Impact factor: 3.454

Review 6.  Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center.

Authors:  D A Weeks; J B Beckwith; G W Mierau; D W Luckey
Journal:  Am J Surg Pathol       Date:  1989-06       Impact factor: 6.394

7.  Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.

Authors:  C M Taylor; B Blanchard; D T Zava
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

Review 8.  Basic guide to the mechanisms of antiestrogen action.

Authors:  J I MacGregor; V C Jordan
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

9.  Primary rhabdoid tumour of the brain.

Authors:  S M Jakate; H B Marsden; L Ingram
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

Review 10.  Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects.

Authors:  R R Love
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

View more
  2 in total

1.  Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

Authors:  Velasco Cimica; Melissa E Smith; Zhikai Zhang; Deepti Mathur; Sridhar Mani; Ganjam V Kalpana
Journal:  BMC Cancer       Date:  2010-11-19       Impact factor: 4.430

2.  Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.

Authors:  Rammohan Devulapally; Thillai V Sekar; Ramasamy Paulmurugan
Journal:  Mol Pharm       Date:  2015-04-28       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.